GlassScriptPhysician profile
David M Jue
NPI 1467470468
$759.88
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $502 · 2020: $154 · 2021: $14.76 · 2022: $25.16 · 2024: $64.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $64.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $64.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.72 | 2019 | |
| Novo Nordisk INC | $94.94 | 2019-2024 | |
| Astellas Pharma US INC | $80.30 | 2019-2020 | |
| Amgen INC. | $71.41 | 2019-2022 | |
| Abbvie INC. | $61.39 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $55.50 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $46.37 | 2019-2020 | |
| Allergan, INC. | $39.67 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.43 | 2019 | |
| Amarin Pharma, INC. | $23.33 | 2020 | |
| Lilly USA, LLC | $22.81 | 2019 | |
| Acadia Pharmaceuticals INC | $19.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.15 | 2019 | |
| Insulet Corporation | $18.88 | 2019 | |
| Seqirus USA INC | $15.37 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.06 | 2019 | |
| Kyowa Kirin, INC. | $13.98 | 2019 | |
| Pfizer INC. | $13.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Jue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.